Exelixis (EXEL)
(Delayed Data from NSDQ)
$29.35 USD
+0.85 (2.98%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.38 +0.03 (0.10%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.35 USD
+0.85 (2.98%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.38 +0.03 (0.10%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth A Momentum B VGM
Zacks News
Exelixis (EXEL) Q1 Earnings: Will the Stock Disappoint?
by Zacks Equity Research
Exelixis, Inc. (EXEL) is scheduled to report first-quarter 2017 results on May 1, after the market close.
Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis
by Zacks Equity Research
Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis
M&As, Pipeline Catalysts to Drive Pharma Sector
by Arpita Dutt
The sector's fundamentals remain strong -- innovation, mergers and acquisitions (M&As), product approvals and positive data flow should act as catalysts.
Exelixis (EXEL) Reports Q4 Earnings, Revenues Beat Y/Y
by Zacks Equity Research
Exelixis, Inc.(EXEL) posted fourth-quarter 2016 earnings of 12 cents, compared with loss of 18 cents per share in the year ago quarter.
Zacks.com featured highlights: Exelixis, U.S. Silica Holdings, Intuit and RPC
by Zacks Equity Research
Zacks.com featured highlights: Exelixis, U.S. Silica Holdings, Intuit and RPC
Cooper (COO) to Report Q1 Earnings: Is a Surprise in Store?
by Zacks Equity Research
The Cooper Companies Inc. (COO) is set to report first-quarter fiscal 2017 results after the market closes on Mar 2.
4 Stocks to Buy with Superb Earnings Acceleration
by Tirthankar Chakraborty
Earnings acceleration helps spot stocks that haven't caught the attention of investors yet, which once secured will invariably lead to a rally in the share price.
Keryx (KERX) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Keryx Biopharmaceuticals, Inc. (KERX) is expected to report fourth-quarter 2016 results on Mar 1.
Radius Health (RDUS) Posts Wider Loss in Q4
by Zacks Equity Research
Radius Health, Inc. (RDUS) posted a loss of $1.22 per share in the fourth quarter of 2016, compared with a loss of 77 cents per share in the year-ago quarter and wider than the Zacks Consensus Estimate loss of $1.16.
What's in the Cards for Box, Inc. (BOX) in Q4 Earnings?
by Zacks Equity Research
Box, Inc. (BOX) is set to report fourth-quarter fiscal 2017 results on Mar 1. Last quarter, the company posted a positive earnings surprise of 14.29%.
Why Earnings Season Could Be Great for Exelixis (EXEL)
by Zacks Equity Research
Exelixis (EXEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
DexCom (DXCM) Q4 Earnings: What to Expect from the Stock?
by Zacks Equity Research
DexCom, Inc. (DXCM) is set to report fiscal fourth-quarter 2017 results on Feb 28.
Tenet Healthcare (THC) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Tenet Healthcare Corporation (THC) will release fourth-quarter 2016 results on Feb 27, after the market closes. Let's see how things are shaping up for this announcement.
Endocyte (ECYT) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Endocyte, Inc (ECYT) is expected to report fourth-quarter 2016 results on Mar 1. The company has an impressive track record, having beaten estimates on three of the trailing four quarters and reporting in-line results in the remaining quarter
Horizon (HZNP) Q4 Earnings: Stock Likely to Disappoint?
by Zacks Equity Research
Horizon Pharma plc (HZNP) is scheduled to report fourth-quarter 2016 results on Feb 27, before the opening bell.
ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time?
by Zacks Equity Research
ACADIA Pharmaceuticals Inc. (ACAD) is expected to report fourth-quarter 2016 results on Feb 28.
TriMas (TRS) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
TriMas Corporation (TRS) is scheduled to report fourth-quarter 2014 results on Feb 28, before the opening bell.
Juno Therapeutics (JUNO) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Juno Therapeutics Inc. (JUNO) is set to report fourth-quarter 2016 results on Mar 1, after the market closes.
Jazz Pharma (JAZZ) Q4 Earnings: Is a Surprise in Store?
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) is scheduled to report fourth-quarter 2016 results on Feb 28 after the market closes.
Endo (ENDP) to Post Q4 Earnings: Will the Stock Disappoint?
by Zacks Equity Research
Endo International plc (ENDP) is scheduled to report fourth-quarter 2016 results on Feb 28, before the opening bell.
Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?
by Zacks Equity Research
Exelixis, Inc. (EXEL) is scheduled to report fourth-quarter 2016 results on Feb 27, after the market close.
Can Penumbra (PEN) Spring a Surprise this Earnings Season?
by Zacks Equity Research
Penumbra Inc. (PEN) is slated to release fourth-quarter 2016 results on Feb 28, after market close.
Intercept (ICPT) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) is scheduled to report fourth-quarter 2016 results on Feb 23.
Ionis (IONS) Q4 Earnings: What's in the Cards for the Stock?
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report fourth-quarter 2016 results on Feb 28.
Patterson Companies (PDCO) Q3 Earnings: What's in Store?
by Zacks Equity Research
Patterson Companies Inc. (PDCO) is set to report fiscal third-quarter 2017 results on Feb 23, before the opening bell.